Ultragenyx Pharmaceutical RARE Payment for (Proceeds from) Other Investing Activity
Payment for (Proceeds from) Other Investing Activity at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForProceedsFromOtherInvestingActivities.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's payment for (proceeds from) other investing activity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's payment for (proceeds from) other investing activity?
- Ultragenyx Pharmaceutical (RARE) reported payment for (proceeds from) other investing activity of $0 in Q1 2026.
- How has Ultragenyx Pharmaceutical's payment for (proceeds from) other investing activity changed year-over-year?
- Ultragenyx Pharmaceutical's payment for (proceeds from) other investing activity decreased by 100.0% year-over-year, from $1M to $0.
- What does payment for (proceeds from) other investing activity mean?
- Net cash flows resulting from investing activities that do not fall under standard categories like securities or loans. This may include investments in joint ventures, real estate, or other non-financial assets. It serves as a catch-all for miscellaneous capital deployment or divestment activities.